Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients

Abstract

Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.